TODOS MED LTD ORD - TOMDF STOCK NEWS

Todos Medical, Ltd. (OTCQB: TOMDF) has signed a lease for a 15,200 square-foot botanical supplement manufacturing facility in Cleburn, TX. This facility will support the production of Tollovid™, a dietary supplement from its subsidiary 3CL Pharma. Equipped with over $2 million in manufacturing technology, it aims to produce up to 30 million bottles monthly. The facility is set to achieve current Good Manufacturing Practices (cGMP) status by the end of 2022, allowing Todos to compete internationally and control its production costs.

Todos Medical, Ltd. (OTCQB: TOMDF) announced the expansion of its clinical laboratory's onsite school sample collection programs to include MonkeyPox testing, alongside COVID-19 PCR testing. The initiative aims to screen school staff and students in the event of confirmed MonkeyPox cases, ensuring public health safety. This service is initially available in select districts in Georgia and New Jersey, with plans for further expansion. The company emphasizes the need for simultaneous testing to identify dual infections and reduce transmission risks.

Todos Medical, Ltd. (OTCQB: TOMDF) announced its Atlanta-based laboratory, Provista Diagnostics, is now offering saliva-only MonkeyPox testing. Samples must be refrigerated within an hour of collection and arrive at the lab within 72 hours. Results are available in 24-48 hours, achieving a sensitivity of 1.2 viral copies per reaction. The test is primarily for suspected cases without lesions. Marketing efforts are underway to inform Atlanta school districts about testing capabilities. The Provista saliva test is available nationwide, excluding New York, where testing is anticipated post-inspection.

Todos Medical Ltd. (OTCQB: TOMDF) announced that its laboratory, Provista Diagnostics, enrolled a female Long COVID patient who was initially denied MonkeyPox testing. This patient has been prescribed TPoxx, and samples will be assessed to evaluate the impact of MonkeyPox on Long COVID biomarkers. With Long COVID affecting up to 25% of children, the study aims to highlight the potential risks of MonkeyPox infections on this vulnerable group, especially in school settings. The press release emphasizes the need for enhanced COVID and MonkeyPox surveillance in schools.

Todos Medical, Ltd. (OTCQB: TOMDF) announced a MonkeyPox diagnostic case study at its CLIA/CAP-certified lab, Provista Diagnostics. The study aims to identify missed diagnoses in non-gay male patients who remain symptomatic for up to 10 weeks. The initial cohort consists of three women and one man, with plans to evaluate multiple test articles for MonkeyPox detection. Additionally, the Company will collaborate with Amerimmune to study MonkeyPox's impact on the immune system, paving the way for new diagnostic tests for active infections and immunity status.

Todos Medical (OTCQB: TOMDF) reported Q2 2022 revenues of $2.18 million, up from $1.73 million in Q2 2021, primarily due to increased COVID testing and Tollovid sales. The company recorded a net loss of $6.78 million compared to a net gain of $3.39 million in Q2 2021, significantly affected by rising interest and amortization expenses. Preparations for an EUA filing for Tollovir™ and a Phase 2 trial for Long COVID are complete. New PCR tests including MonkeyPox have launched, with a focus on underserved areas. The company aims for a national exchange listing within 12 months.

Todos Medical, Ltd. (OTCQB: TOMDF) has announced its Provista Diagnostics lab is ready to commercially launch PCR-based MonkeyPox testing in the U.S., having completed CLIA validation with a sensitivity of 1.2 viral copies per reaction. The company is preparing an IgM/IgG MonkeyPox LDT to confirm recent infections. With the U.S. experiencing a MonkeyPox public health emergency, Provista aims to increase testing capacity from 25,000 to 50,000 PCR tests per day to support outbreak containment efforts. A Q2 10Q report will be released today, followed by a business update call on August 23.

Todos Medical Ltd. (OTCQB: TOMDF) announced positive preliminary results from a joint venture study on the use of 3CL protease inhibitors for treating Long COVID and acute COVID patients. The study, led by Dr. Dorit Arad, involved 100 participants and indicated benefits from the immune support supplement, Tollovid. This is significant due to the critical role of 3CL protease in the SARS-CoV-2 virus's replication. Tollovid is available for purchase on Amazon and other platforms, supporting Todos’ focus on immune health and diagnostics.

Todos Medical (OTCQB: TOMDF) announced a preprint case study showing the limited benefits of COVID-19 vaccinations for two patients suffering from Long COVID, who saw significant improvement after using the supplement Tollovid. The study highlights the need for alternative solutions in treating lingering COVID symptoms. Tollovid is designed to support immune function and inhibit 3CL protease activity. The company’s joint venture, 3CL Pharma, is focused on developing protease inhibitors for COVID-19 and other coronaviruses. The press release emphasizes the importance of ongoing research and product development.